Financial Statements — MDCX
Balance Sheet
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q3
2025 | Q2
2025 | Q1
2025 |
|---|
| Cash & Equivalents | 15.17 | 6.37 | 8.66 | 9.67 | 3.98 |
| Total Current Assets | 16.98 | 7.28 | 9.78 | 11.00 | 5.09 |
| Total Non-current Assets* | 10.13 | 0.14 | 0.20 | 0.94 | 0.57 |
| Total Assets | 27.12 | 7.43 | 9.98 | 11.93 | 5.66 |
| Accounts Payable | 0.31 | 1.04 | 1.56 | 1.83 | 1.06 |
| Short-term Debt | -- | 2.34 | 6.79 | 4.70 | -- |
| Total Current Liabilities | 10.84 | 5.95 | 10.66 | 8.54 | 3.34 |
| Total Non-current Liabilities* | 18.00 | 0.05 | 0.12 | 0.14 | 0.17 |
| Total Liabilities | 28.84 | 6.00 | 10.78 | 8.69 | 3.51 |
| Retained Earnings | (85.01) | (73.39) | -0.00 | (40.18) | (34.01) |
| Total Stockholder Equity* | (1.76) | 1.33 | (0.91) | 3.25 | 2.15 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 | Q2
2025 | Q1
2025 | Q4
2024 |
|---|
| Research & Development | 4.91 | 2.70 | 2.59 | 1.68 | 1.44 | 2.01 | 1.37 |
| Selling, General & Admin | 6.57 | 5.89 | 10.22 | 0.00 | 4.58 | 3.12 | 2.22 |
| Total Operating Expenses | 11.48 | 8.60 | 23.22 | 0.00 | 6.02 | 5.13 | 3.59 |
| Operating Income | (11.48) | (8.60) | (23.22) | -0.00 | (6.02) | (5.13) | (3.59) |
| Interest Expense | 0.21 | 0.37 | -- | -- | -- | -- | -- |
| Net Income | (11.62) | (9.04) | (15.07) | (20.94) | (3.63) | (5.10) | (3.54) |
| Basic EPS | (0.21) | (0.31) | (0.77) | (1.12) | (0.43) | (0.42) | (0.27) |
| Diluted EPS | (0.21) | (0.31) | (0.77) | (1.12) | (0.43) | (0.42) | (0.27) |
Cash Flow Statement
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 | Q2
2025 | Q1
2025 |
|---|
| Operating Cash Flow | (6.98) | (8.97) | (6.61) | (6.76) | (5.47) | (3.94) |
| Investing Cash Flow | -- | -- | -- | (4.62) | -- | -- |
| Financing Cash Flow | 25.53 | 6.83 | 6.65 | 10.37 | 11.16 | 3.76 |
